Salmonella Typhimurium has been used in immunotherapies in murine trials, with significant tumor reduction, resulting from the local expression of bacteria or the expression of immune system-stimulating molecules on tumor cells IL-18, CCL21, LIGHT, or the Fas ligand [148]. Here, FASLG is linked to neoplasm.